CytomX Therapeutics, Inc. (CTMX)

1,9200 +0,0300 (+1,59%) Alla chiusura: 04:00PM EDT

CytomX Therapeutics, Inc.

151 Oyster Point Boulevard
Suite 400
South San Francisco, CA 94080
United States
650 515 3185
https://www.cytomx.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 120

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Sean A. McCarthy DPHIL	Chairman & CEO	1,03M	N/D	1967
Dr. Marcia P. Belvin Ph.D.	Senior VP & Chief Scientific Officer	634,83k	N/D	N/D
Mr. Jeffrey Landau B.S., M.B.A.	Senior VP, Head of Strategy & Chief Business Officer	580,69k	N/D	1979
Mr. Christopher W. Ogden	Senior VP of Finance & Accounting	N/D	N/D	1984
Mr. Lloyd A. Rowland Jr., J.D.	Senior VP, General Counsel, Chief Compliance Officer & Secretary	608,72k	N/D	1957
Ms. Danielle Olander-Moghadassian	Senior VP & Chief Human Resources Officer	N/D	N/D	N/D
Ms. Leslie Robbins	Senior Vice President of Intellectual Property	N/D	N/D	N/D
Dr. Yu-Waye Chu M.D.	Chief Medical Officer	N/D	N/D	1968
Ms. Dawn Benson	Senior Vice President of Quality & Product Manufacturing	N/D	N/D	N/D
Dr. Hoyoung Huh M.D., Ph.D.	Special Advisor to Chief Executive Officer	72,5k	N/D	1969

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Governance aziendale

L'ISS Governance QualityScore di CytomX Therapeutics, Inc. al 1 maggio 2024 è 6. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 8; diritti degli azionisti: 3; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.